Nakjeong Kim
Chungnam National University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nakjeong Kim.
Bioorganic & Medicinal Chemistry Letters | 2003
Nakjeong Kim; Sun-Kyung Lee; Kyu Yang Yi; Sung-Eun Yoo; Guncheol Kim; Chong Ock Lee; Sung Hee Park; Byung Ho Lee
A series of 4-(N-imidazol-2-ylmethyl)aminobenzopyran analogues, originally designed as K(ATP) openers for ischemic diseases, showed antiangiogenic properties through the inhibition of HUVEC tube formation. Especially one of p-Cl substituted analogues (4c) completely inhibited HUVEC tube formation at 10 microM. The compound 4c significantly inhibited tumor growth by 52% on A549 (human non small cell lung carcinoma) in nude mice xenografts without any significant side effects.
Bioorganic & Medicinal Chemistry Letters | 2013
Tuong Vy Thi Le; Jee Hee Suh; Nakjeong Kim; Hyun-Ju Park
Poly(ADP-ribose)polymerase-1 (PARP-1) enzyme is involved in the repair of DNA damages made by certain anticancer agents. It is suggested that PARP-1 inhibitors potentiate the cytotoxic effects and circumvent the resistance of DNA-modifying anticancer agents such as cisplatin. In this study, we conducted virtual screening of Korea Chemical Bank database targeting PARP-1 and identified several potent PARP-1 inhibitors with submicromolar IC50 values (77-79 nM). We then examined the chemosensitization of cisplatin by pre-treatment of PARP-1 inhibitors in cisplatin-resistant human gastric cancer cells. Our results show that PARP-1 inhibitors suppress the formation of poly(ADP-ribose) and enhance the cytotoxicity of cisplatin.
Bioorganic & Medicinal Chemistry Letters | 2011
Chae Jo Lim; Nakjeong Kim; Eun Kyoung Lee; Byung Ho Lee; Kwang-Seok Oh; Sung-eun Yoo; Kyu Yang Yi
Compounds containing 2-arybenzimidazole ring systems linked to arylpiperidines were synthesized and evaluated as MCH-R1 antagonists. The results of structure-activity relationship studies led to the identification of compound 4c as a potent MCH-R1 antagonist (IC(50)=1 nM). This compound also has good metabolic stability, and favorable pharmacokinetic and brain penetration properties. However 4c was found to be potent inhibitor of the hERG potassium channel.
Bioorganic & Medicinal Chemistry Letters | 2013
Byung Jun Ryu; Nakjeong Kim; Jun Tae Kim; Tae-Sung Koo; Sung-Eun Yoo; Seo Hee Jeong; Seong Hwan Kim; Nam Sook Kang
In this study, we synthesized the BF-3 binding small molecules, a series of pyridazinone-based compounds, as a novel class of non-LBP antiandrogens for treating prostate cancer by inhibiting androgen receptor. The new class compound was discovered to inhibitor the viability of AR-dependent human prostate LNCap cells and AR activity combining with the computational method. It showed a good physicochemical and PK property.
Journal of Medicinal Chemistry | 2001
Sung-Eun Yoo; Kyu Yang Yi; Sun-Kyung Lee; Jeehee Suh; Nakjeong Kim; Byung Ho Lee; Ho Won Seo; Sun-Ok Kim; Dong Ha Lee; Hong Lim; Hwa Sup Shin
Journal of Organic Chemistry | 2003
Guncheol Kim; Sung-do Jung; Eun-Ju Lee; Nakjeong Kim
Tetrahedron Letters | 2007
Guncheol Kim; Nakjeong Kim
Tetrahedron Letters | 2005
Guncheol Kim; Nakjeong Kim
Archive | 2001
Sung-Eun Yoo; Kyu Yang Yi; Sun Kyung Lee; Nakjeong Kim; Jee Hee Suh; Young Sook Park; Sun Kyung Hwang; Hwa Sup Shin; Byung Ho Lee; Ho Won Seo; Hong Lim; Sun-Ok Kim; In Sun Cho; Miae Namgoong; Dongsoo Jang
Journal of Photochemistry and Photobiology A-chemistry | 2005
Nakjeong Kim; Kyu Yang Yi; Sung-Eun Yoo; Guncheol Kim; Seung Ki Park